Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer

Study acronym: Hypo-Combi
StatusActive, Not Recruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Unknown → Active, Not Recruiting
    • Study completion pushed from Aug 1, 2026 to Aug 1, 2027
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 2 of 6 entries
  2. Changed Registry marked status Unknown; last known: Active, Not Recruiting
  3. Trial status: Recruiting to Unknownv2 Show 5 more changesShow less
    • Primary completion date changed from estimate of Jul 1, 2023 to Dec 31, 2022
    • Study completion date: Jul 1, 2026 to Aug 1, 2026
    • Secondary endpoints revised (6)
    • Site details revised
    • Study arms: 0 to 1
  4. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hypo-Combi Trial: A Prospective Phase I/II Study of Combined Hypofractionated External Beam Radiation Therapy (EBRT) plus Interstitial High-Dose-Rate Brachytherapy (HDR-BT) for Intermediate/High Risk Prostate Cancer
Trial Details
NCT Number NCT05003752
Lead Sponsor German Oncology Center, Cyprus
Conditions
(from sponsor)		 Prostate Adenocarcinoma, Radiation Toxicity
Related terms Prostatic Neoplasms, Radiation Injuries
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov